Kurs
-0,77%
Likviditet
0,16 MSEK
Kalender
| Tid* | ||
| 2025-07-24 | 07:30 | Kvartalsrapport 2025-Q3 |
| 2025-04-25 | 07:30 | Kvartalsrapport 2025-Q2 |
| 2025-01-30 | 07:30 | Kvartalsrapport 2025-Q1 |
| 2024-11-29 | - | X-dag ordinarie utdelning NXTCL 0.00 SEK |
| 2024-11-28 | - | Årsstämma |
| 2024-10-24 | - | Bokslutskommuniké 2024 |
| 2024-07-25 | - | Kvartalsrapport 2024-Q3 |
| 2024-05-27 | - | Extra Bolagsstämma 2024 |
| 2024-04-25 | - | Kvartalsrapport 2024-Q2 |
| 2024-01-25 | - | Kvartalsrapport 2024-Q1 |
| 2023-12-01 | - | X-dag ordinarie utdelning NXTCL 0.00 SEK |
| 2023-11-30 | - | Årsstämma |
| 2023-10-26 | - | Bokslutskommuniké 2023 |
| 2023-07-27 | - | Kvartalsrapport 2023-Q3 |
| 2023-04-27 | - | Kvartalsrapport 2023-Q2 |
| 2023-01-26 | - | Kvartalsrapport 2023-Q1 |
| 2022-11-25 | - | X-dag ordinarie utdelning NXTCL 0.00 SEK |
| 2022-11-24 | - | Årsstämma |
| 2022-10-27 | - | Bokslutskommuniké 2022 |
| 2022-07-28 | - | Kvartalsrapport 2022-Q3 |
| 2022-04-28 | - | Kvartalsrapport 2022-Q2 |
| 2022-01-27 | - | Kvartalsrapport 2022-Q1 |
| 2021-11-25 | - | X-dag ordinarie utdelning NXTCL 0.00 SEK |
| 2021-11-24 | - | Årsstämma |
| 2021-10-29 | - | Bokslutskommuniké 2021 |
| 2021-07-30 | - | Kvartalsrapport 2021-Q3 |
| 2021-04-29 | - | Kvartalsrapport 2021-Q2 |
| 2021-01-29 | - | Kvartalsrapport 2021-Q1 |
| 2020-11-25 | - | X-dag ordinarie utdelning NXTCL 0.00 SEK |
| 2020-11-24 | - | Årsstämma |
| 2020-10-30 | - | Bokslutskommuniké 2020 |
| 2020-07-31 | - | Kvartalsrapport 2020-Q3 |
| 2020-06-03 | - | Extra Bolagsstämma 2020 |
| 2020-04-30 | - | Kvartalsrapport 2020-Q2 |
| 2020-01-31 | - | Kvartalsrapport 2020-Q1 |
| 2019-12-06 | - | X-dag ordinarie utdelning NXTCL 0.00 SEK |
| 2019-12-05 | - | Årsstämma |
| 2019-10-31 | - | Bokslutskommuniké 2019 |
| 2019-07-31 | - | Kvartalsrapport 2019-Q3 |
| 2019-04-30 | - | Kvartalsrapport 2019-Q2 |
| 2019-01-31 | - | Kvartalsrapport 2019-Q1 |
| 2018-12-05 | - | Årsstämma |
| 2018-11-01 | - | X-dag ordinarie utdelning NXTCL 0.00 SEK |
| 2018-10-31 | - | Bokslutskommuniké 2017 |
| 2018-07-31 | - | Kvartalsrapport 2017-Q3 |
| 2017-12-06 | - | X-dag ordinarie utdelning NXTCL 0.00 SEK |
| 2017-12-05 | - | Årsstämma |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
NextCell Pharma AB ("NextCell" or the "Company") today announces that the Swedish Health and Social Care Inspectorate (IVO) has granted their Cellaviva tissue establishment permission to handle amniotic tissue. Cellaviva is the largest private stem cell bank in the Nordics. Since the launch of the cord blood bank in 2014, the company has increased the business model to include genetic tests and tissue handling services for biotech companies and hospitals.
Cellaviva is expanding business-to-business activities by broadening their tissue establishment permission to include aminiotic tissues. This opens up the opportunity for handling ophthalmic products which often are produced from amniotic tissue. Discussions potential suppliers are ongoing. The business model is fee for service. Cellaviva provides a service for handling, shipping and traceability of tissues which require a tissue establishment.
Mathias Svahn, CEO
Patrik Fagerholm, CFO
Tel: +46 8 735 55 95
E-mail: info@nextcellpharma.com
Website:www.nextcellpharma.com
Linkedin: https://www.linkedin.com/NextCell-Pharma (https://www.linkedin.com/company/15255207/)
Twitter: https://twitter.com/NextCellPharma
For more information about Cellaviva, please contact
Sofie Falk Jansson, Head of Cellaviva
Tel: +46 8 735 20 10
E-mail: info@cellaviva.se (info@nextcellpharma.com)
Website:www.cellaviva.se (http://www.nextcellpharma.com)
Facebook: https://www.facebook.com/cellavivasverige (https://www.linkedin.com/company/15255207/)
Instagram: https://www,instagram.com/cellaviva (https://twitter.com/NextCellPharma)